[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma

  • STATUS
    Recruiting
  • End date
    Jun 25, 2025
  • participants needed
    35
  • sponsor
    Won Seog Kim
Updated on 13 February 2022
methotrexate
cytarabine
rituximab
measurable disease
antiretroviral therapy
serum bilirubin
neutrophil count
b-cell lymphoma
nervous
hodgkin's lymphoma

Summary

This study was conducted to evaluate the 2-year progression free survival rate of elderly patients with primary CNS lymphoma followed by combination of rituximab and methotrexate followed by rituximab and cytarabine.

Description

As described, standard therapy for patients with primary CNS lymphoma is not based on a high level of evidence yet, and studies in elderly patients with this disease are very limited. Based on the Korea National Cancer Incidence Database, it is estimated that about 100 ~ 150 cases of primary central nervous system lymphoma are diagnosed per year in Korea, but there is no analysis through prospective studies. As described previously, MTX monotherapy in elderly patients is relatively safe and does not reduce clinical utility. Although the autologous therapy may consider autologous stem cell transplantation, it is difficult to apply in elderly patients. Brain radiation therapy is not a primary consideration because it may cause neurological sequelae, especially in elderly patients. High-dose cytarabine is a safely administered drug that has been used extensively in clinical studies involving the treatment of elderly patients.Rituximab has not been studied prospectively for medications, doses, and intervals that are expected to play a role in patients with primary CNS lymphoma, as described above, and may be caused by reducing the number of cytotoxic anticancer drugs in elderly patients And to reduce the treatment effect.

Therefore, the authors propose a two-phase study in which R-A induction therapy is performed after R-M induction therapy in elderly patients with primary CNS lymphoma.

Details
Condition Primary CNS Lymphoma
Treatment Rituximab, methotrexate, cytarabine, Cytarabine Injection
Clinical Study IdentifierNCT03569995
SponsorWon Seog Kim
Last Modified on13 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically proven diagnosis of B-cell non-Hodgkin's lymphoma, exclusively localized in the central nervous system, cranial nerves, and/or eyes
No previous treatment; A tumorectomy on diagnostic purpose and/or use of glucocorticoids is allowed
Measurable lesion(s)
Age 60 years
Unfit patients for high-dose chemotherapy followed by autologous stem cell transplantation
Adequate organ functions
Absolute Neutrophil Count (ANC) 1.0 x 109/L
Platelets 50 x 109/L
Hemoglobin 8.0 g/dL
Serum Creatinine 1.5 x upper limit normal (ULN)
Serum Bilirubin 1.5 x ULN
AST and ALT 3 x ULN
Patients with adequately controlled HBV, HCV or HIV are allowed. In case of HBV (+), adequate anti-viral prophylaxis should be incorporated. In case of HIV (+), highly active anti-retroviral therapy should be incorporated
Written informed consent
ECOG performance scale 0, 1 or 2
Life expectancy > 3 months

Exclusion Criteria

T-cell or NK/T cell lymphoma
Any evidence of systemic non-Hodgkin's lymphoma as demonstrated by computed tomography scan of the neck, chest, abdomen, and pelvis and bone marrow examinations
Young and fit patients who are suitable for high-dose chemotherapy followed by autologous stem cell transplantation
Prior radiation therapy on target CNS lesion(s)
Concurrent severe or uncontrolled medical conditions, laboratory abnormalities or psychiatric disorders that would preclude the participants in the study by the discretion of attending physicians
Metachronous malignancy other than adequately treated basal cell or squamous cell carcinoma of the skin, or CIN of uterine cervix, or prostate cancer that can be observed without treatment
Known hypersensitivity to the investigational agent(s)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note